RepRegen CE marks tissue regeneration product
This article was originally published in Clinica
RepRegen has CE marked StronBone, a biomaterial designed to repair and regenerate hard tissue, for sale in the EU. The product is a bioactive glass containing strontium, which boosts performance of bioceramics for bone repair, RepRegen says. The London, UK firm, formerly known as BioCeramic Therapeutics, said that the approval would allow it to accelerate discussions with potential strategic partners about its hard tissue product platform in general and StronBone in particular. RepRegen's other hard tissue repair products are geared towards the orthopaedic market, including some to address trauma and spinal defects, and craniomaxillofacial applications.
You may also be interested in...
Dr Noam Emanuel is the founder and chief technology officer of Ness Ziona, Israel-based drug delivery firm PolyPid. The 15-strong firm, established in 2008, has developed an encapsulation technology which allows the precise targeting of drug release.
Mesoblast has received the all-clear from the US FDA to start a Phase III clinical trial for bone marrow regeneration in patients with blood cancers. The study will be conducted together with Mesoblast's strategic alliance partner, Cephalon, which will fund the trial.
Mesoblast has received the green light from the US FDA to begin a Phase II trial of its proprietary adult mesenchymal precursor cell (MPC) product for the treatment of degenerative disc disease, a major cause of chronic low back pain.